Erasca Inc
Gesloten
13.4 4.44
Overzicht
Wijziging aandelenprijs
24u
Min
12.22
Max
13.41
Inkomsten | -154M -183M |
|---|---|
EPS | -0.6 |
Werknemers | 103 |
EBITDA | -5.3M -37M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +63.17% upside |
Volgende Winsten | 10 aug 2026 |
|---|
Marktkapitalisatie | 476M 3.7B |
|---|---|
Vorige openingsprijs | 8.96 |
Vorige sluitingsprijs | 13.4 |
Erasca Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Erasca Inc Prognose
Koersdoel
By TipRanks
63.17% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 21 USD 63.17%
Hoogste 30 USD
Laagste 12 USD
Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Erasca Inc - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
